Modulation of glycogen synthase kinase- 3β following TRAIL combinatorial treatment in cancer cells

Supplementary Materials

| Cell Type | LNCaP | | | | | | | |
|--|-------|-------|---|---|--------|-------|---------------|---|
| Treatment Time | 16hrs | | | | | | | |
| GSK3β Inhibitor VIII (10μM) | - | | | | + | | | |
| TRAIL | - | - | + | + | - | - | + | + |
| TZD | - | + | - | + | - | + | - | + |
| DMSO | + | - | - | - | + | - | - | - |
| Cl Cas3→ | - | - | = | ₹ | Minus. | - | = | = |
| $PARP \begin{vmatrix} FL \rightarrow \\ Cl \rightarrow \end{vmatrix}$ | 1 | - | = | = | - | _ | _ | _ |
| Cl Cas9 \rightarrow Cl Cas8 $ (p43/41) \rightarrow $ $(p18) \rightarrow$ | 100 | en co | - | = | - | No. | MARKET STREET | - |
| | - | 800 | - | - | 100 | telle | - | - |
| | | | - | - | | | - | - |
| pGS ^{Ser641} → | • | - | - | - | - | - | W1-18 | |
| GS → | - | - | - | - | - | - | - | |
| GAPDH → | - | _ | _ | _ | _ | _ | _ | _ |

Supplementary Figure S1: Effect of GSK3 β inhibitor VIII on TRAIL-TZD-induced apoptosis. LNCaP cells were pretreated with 10 μ M GSK3 β inhibitor VIII for 1 hr followed by treatment with DMSO, TZD, TRAIL or TRAIL-TZD combination for 16 hrs. The samples were analyzed by Western blots with the indicated antibodies.

| Cell Type | LNCaP | | | | | | | | | |
|-------------------------|-------|--------|--------------|---------|-------|------|----|----|--|--|
| Treatment Time | 16hrs | | | | | | | | | |
| Kenpaullone (10μM) | - | | | | + | | | | | |
| TRAIL | - | - | + | + | - | - | + | + | | |
| TZD | - | + | - | + | - | + | - | + | | |
| DMSO | + | • | - | - | + | - | - | 1 | | |
| Cl Cas3 → | - | 100 mg | and the same | | SON . | RIE. | - | 1 | | |
| PARP FL→ Cl→ | 8 | - | 80 | 203 | Ett | 800 | 88 | 1 | | |
| pGS ^{Ser641} → | 1 | mon | _ | and the | - | - | _ | 99 | | |
| GS → | 1 | _ | - | - | _ | _ | _ | - | | |
| GAPDH → | 1 | - | _ | - | _ | _ | - | - | | |

Supplementary Figure S2: Effect of Kenpaullone on TRAIL-TZD-induced apoptosis. LNCaP cells were pretreated with $10~\mu M$ Kenpaullone (GSK3 β inhibitor) for 1 hr followed by treatment with DMSO, TZD, TRAIL or TRAIL-TZD combination as in Supplementary Figure S1 and Western blot analyses.